{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"12"}]}],"title":"<25 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"125"}]}],"title":">=25 to <50 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"245"}]}],"title":">=50 to <90 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"58"}]}],"title":">=90 to <150 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"title":">=150 to <200 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":">=200 to <400 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":">=400 Gi/L"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"450"}],"units":"Participants"}],"description":"The minimum platelet count with antiviral therapy was categorized as follows: \\<25 Gi/L; \\>=25 to \\<50 Gi/L; \\>=50 to \\<90 Gi/L; \\>=90 to \\<150 Gi/L; \\>=150 Gi/L to \\<200 Gi/L; \\>=200 Gi/L to \\<400 Gi/L; and \\>=400 Gi/L.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy During the DB Phase","type":"SECONDARY","unitOfMeasure":"participants"}